胰岛素强化治疗可以控制危重患者的目标血糖控制（Target Glucose Control，TGC）在4．4～6．1mmol／L之间，从而大大降低相关的临床并发症和病死率。
基于4个网页-相关网页
Sirtris已经开始了其中一种的临床试验，这种改进型的白藜芦醇目标是控制糖尿病患者的血糖水平。
Sirtris has begun clinical trials of one of these compounds, an improved version of resveratrol, with the aim of seeing if it helps control glucose levels in people with diabetes.
ICU患者的最佳血糖控制目标仍然是一个不确定领域，尚未在接受肠外营养的患者中进行过专门研究。
The optimal target for blood glucose control in ICU patients remains an area of uncertainty and has not been specifically investigated in patients receiving parenteral nutrition.
ACCORD研究显示随着血糖控制目标的接近，全因死亡率出现了增高。
ACCORD demonstrated that the closer we control to glucose targets, there is an increase in all cause mortality.
应用推荐